Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD. METHOD: In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness, and distractibility. RESULTS: Sixty-two subjects (boys, N=53; girls, N=9; mean age=8.5 years [SD=2.25]) were randomly assigned to guanfacine (N=30) or placebo (N=32) for 8 weeks. The guanfacine group showed a 43.6% decline in scores on the Aberrant Behavior Checklist-hyperactivity subscale (least squares mean from 34.2 to 19.3) compared with a 13.2% decrease in the placebo group (least squares mean from 34.2 to 29.7; effect size=1.67). The rate of positive response (much improved or very much improved on the Clinical Global Impression-Improvement scale) was 50% (15 of 30) for guanfacine compared with 9.4% (3 of 32) for placebo. A brief cognitive battery tapping working memory and motor planning showed no group differences before or after 8 weeks of treatment. The modal dose of guanfacine at week 8 was 3 mg/day (range: 1-4 mg/day), and the modal dose was 3 mg/day (range: 2-4 mg/day) for placebo. Four guanfacine-treated subjects (13.3%) and four placebo subjects (12.5%) exited the study before week 8. The most common adverse events included drowsiness, fatigue, and decreased appetite. There were no significant changes on ECG in either group. For subjects in the guanfacine group, blood pressure declined in the first 4 weeks, with return nearly to baseline by endpoint (week 8). Pulse rate showed a similar pattern but remained lower than baseline at endpoint. CONCLUSIONS: Extended-release guanfacine appears to be safe and effective for reducing hyperactivity, impulsiveness, and distractibility in children with ASD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A large trial of balovaptan, a vasopressin AVPR1A antagonist in adults with ASD showed negative results on its primary outcome ( a general rating of ASD symptoms), with suggestive results on a key secondary parent report measure of adaptive behaviour, including social and communication behaviour 212 .”
From Autism spectrum disorder (2020) · cites this paper as [212]
In the citing paper
“The results of this trial indicated that guanfacine ER is safe and efficacious for the short-term treatment of ADHD symptoms in children and adolescents with ASD [83].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“The guanfacine group had a 50% positive response rate on the Clinical Global Impressions-Improvement (CGI-I) scale compared to 9.4% for placebo.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“ABC-Hyperactivity subscale scores fell by 43.6% in the active treatment group and 13.2% in the placebo group.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“Drowsiness, fatigue, emotional/tearful presentation, dry mouth, and irritability were the most common side effects in the active treatment arm.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318179964f · Cited by 3,399
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Global Prevalence of Autism and Other Pervasive Developmental Disorders
Elsabbagh, M., Divan, G., Koh, Y., Kim, Y. S., Kauchali, S., Marcín, C., Montiel‐Nava, C., Patel, V., Paula, C. S., Wang, C., et al. (2012) · Autism Research · doi:10.1002/aur.239 · Cited by 2,636
Mullen Scales of Early Learning
Bradley-Johnson, S. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<379::aid-pits14>3.0.co;2-e · Cited by 2,325
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Thompson Coon, J. (2002) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05480.x · Cited by 1,744
Stanford-Binet Intelligence Scale
(2012) · SpringerReference · doi:10.1007/springerreference_70151 · Cited by 1,664
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Self-citation
Research works printed but not linked: 7
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders-Text Revised
- Sparrow SS, 2005, Vineland-II Adaptive Behavior Scales
- Aman MG, 1985, Am J Ment Defic, 89, 485
- Elliott C, 2007, Differential Ability Scales-II (DAS-II)
- Korkman M, 2007, NEPSYII: Administration Manual
- Board AW, 1988, Clin Ther, 10, 761
- 10.1093/biostatistics/kxh001 · DOI · Paper page
Cited by
Items 101–200 of 218
Wallace, K., Uchitel, J., Prange, L., Jasien, J., Bonner, M., D’Alli, R., Maslow, G., & Mikati, M. A. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.06.012 · Cited by 11
Neurodevelopmental Disorders: Autism Spectrum Disorder
Thom, R. P., Friedman, N. D. B., Nasir, R. H., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_36-1 · Cited by 10
Self-citationGuthrie, D. B., Boorin, M. R., Sisti, A. R., Epstein, R. H., Romeiser, J. L., Lam, D. K., Gan, T. J., & Bennett‐Guerrero, E. (2021) · Anesthesia Progress · doi:10.2344/anpr-67-04-02 · Cited by 9
Neurodevelopmental Disorders: Autism Spectrum Disorder
Thom, R. P., Friedman, N. D. B., Nasir, R. H., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_36 · Cited by 9
Self-citationTùnesi, S., Bosio, M., & Russo, A. G. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030844 · Cited by 9
Psychopharmacology of Neurodevelopmental Disorders in Children
Singh, J., & Santosh, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-3619-1_18 · Cited by 9
Attention Deficit Hyperactivity Disorder
Deb, S. S., Perera, B., & Bertelli, M. O. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_17 · Cited by 8
Novel therapeutics in autism spectrum disorder
Kevelson, S. D., Elmaghraby, R., Patel, F., Brown, H. R., Gorenstein, M., Bain, J., Grinspan, Z. M., Pedapati, E. V., Veenstra-VanderWeele, J. M., & Vandana, P. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00857 · Cited by 7
Robb, A. S., Connor, D. F., Amann, B. H., Vitiello, B., Nasser, A. F., O’Neal, W., Schwabe, S., Ceresoli‐Borroni, G., Newcorn, J. H., Candler, S. A., et al. (2020) · CNS Spectrums · doi:10.1017/s1092852920001224 · Cited by 7
Chung, U., & Kim, J.-H. (2024) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.230006 · Cited by 7
Psychopharmacology Management in Autism Spectrum Disorder
Salpekar, J. A., & Scahill, L. D. (2024) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2023.12.001 · Cited by 8
Self-citationWang, F., Wen, F., Yu, L., Yan, J., Liu, J., Li, Y., & Cui, Y. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000349 · Cited by 7
Singh, D., Silver, M., & Jacob, T. (2025) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.33032 · Cited by 6
Age of machine learning: new trends in autism spectrum disorder prediction
Xu, W., Li, H., Li, J., & Jin, M. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1492484 · Cited by 6
Scahill, L. D., Shillingsburg, M. A., Ousley, O., Pileggi, M. L., Kilbourne, R. L., Buckley, D., Gillespie, S. E., & McCracken, C. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2021.11.034 · Cited by 6
Self-citationPowers, J. H., Wu, M. C., Palumbo, M., Keary, C. J., McDougle, C. J., Ravichandran, C. T., & Thom, R. P. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.0069 · Cited by 6
Self-citationGuanfacine for irritability, impulsivity, and agitation in elderly patients: A report of two cases
Miyoshi, T., Noborio, Y., Hoonhwa, C., & Ishimori, Y. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.14 · Cited by 5
Temeltürk, R. D., Ekici, G. İ., Efendi, G. Y., & Kılıç, B. G. (2023) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2023.23690 · Cited by 5
Evidence-Based Pharmacotherapy for Autism Spectrum Disorders
McClellan, L., Pedapati, E. V., Wink, L. K., & Erickson, C. A. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0077-6 · Cited by 5
Stimulant intolerance in children with Angelman syndrome with hyperactivity: a case series
Keary, C. J., Thom, R. P., & McDougle, C. J. (2021) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000307 · Cited by 5
Self-citationPharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities
Hodgins, G. E., Winsor, K., & Barnhill, J. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00517-y · Cited by 4
Schöttle, D., SCHIMMELMANN, B. G., & van Elst, L. T. (2019) · Nervenheilkunde · doi:10.1055/a-0959-2034 · Cited by 4
Transtorno do espectro autista em crianças e adolescentes: intervenções farmacológicas
Suleiman, N. M. A. S., Ferreira, B. D. R. S., de Moraes, L. G., Teixeira, D. A., de Cerqueira, A. M., & Guedes, C. M. D. N. (2025) · Journal of Medical and Biosciences Research. · doi:10.70164/jmbr.v2i4.825 · Cited by 3
Autism Spectrum Disorder (ASD)
Rutten, M. R., Zhong, J., Rolison, M. J., & Sukhodolsky, D. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00076-2 · Cited by 3
Treatment of affective dysregulation in ADHD with guanfacine: study protocol
Waltereit, J., Uhlmann, A., Tarassidis, C., Preuss, U., Roessner, V., & Waltereit, R. (2025) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2025.1547672 · Cited by 3
Psychopharmacology of neurobehavioral disorders
Mooney, L. N., Dominick, K. C., & Erickson, C. A. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00023-x · Cited by 3
Integrating Treatment for Autism: Psychiatric Comorbidities and Comprehensive Treatment
Parenteau, C. I., Tsipan, R. M., & Hendren, R. L. (2021) · Autism and Developmental Disorders · doi:10.17759/autdd.2021190105 · Cited by 3
Clark, B., & Bélanger, S. A. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxy112 · Cited by 3
Psychopharmacology of Autism Spectrum Disorders
Mooney, L. N., Fosdick, C., & Erickson, C. A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108297769.008 · Cited by 3
Liu, T. R., Deardorff, M. A., & Jeste, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00076-7 · Cited by 3
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg005 · Cited by 3
Walitza, S., Smigielski, L., & Gerlach, M. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_8 · Cited by 2
Albanna, A., Sultan, M. A., Derby, H., Arjamand, F., Alshuaibat, S., Alloub, Z., Alhejailan, R., Kair, H. M., Helou, M., Obaid, H. A. M., et al. (2024) · Dubai Medical Journal · doi:10.18502/dmj.v7i4.17808 · Cited by 2
Osmanlı, C. Ç., Baykal, S., Önal, B. S., Şahin, B., & Bozkurt, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-29252-3 · Cited by 2
Transition-Age Youth with Autism Spectrum Disorder
Gwynette, M. F., Marrus, N. M., & Vasa, R. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-62113-1_11 · Cited by 2
Grater, J. E., Muñiz, E. I., Silver, E. J., Blum, N. J., Shults, J., & Stein, R. E. K. (2022) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-022-05611-1 · Cited by 2
Siafis, S., & Leucht, S. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.02.012 · Cited by 2
Neuroleptic Malignant Syndrome in a Patient with Autism Spectrum Disorder: Case Report
Klek, S., Newgren, J., Burns, P., Kwak, A., Casinelli, E., Tu, T., Pontikes, T. K., & Meresh, E. S. (2023) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2304188 · Cited by 2
Thom, R. K., Thom, R. P., & McDougle, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-46463-8_9 · Cited by 2
Self-citationBartel, R. L., Knight, J. R., Worsham, W., & Bilder, D. A. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20230027 · Cited by 2
Mori, H., Ochi, S., Hashida, H., Iga, J., & Ueno, S. (2025) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.24.1263 · Cited by 2
Effective Medications for Treating Individuals with Autism Spectrum Disorder
Farmer, C., Leon, J., & Hommer, R. E. (2019) · Pediatric school psychology · doi:10.1007/978-3-030-15541-4_6 · Cited by 2
Neurological evaluation and management of autism spectrum disorder
Goodspeed, K., Haffner, D. N., Golla, S., Morris, M. A., & Evans, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00023-4 · Cited by 2
Chapter 7. Autism Spectrum Disorder
Palumbo, M. L., Keary, C. J., & McDougle, C. J. (2017) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371266.lg07 · Cited by 2
Self-citationChapter 5. Pediatric and Neurological Assessment and Targeted Treatments
Ligsay, A., Bain, J., Veenstra-VanderWeele, J. M., & Hagerman, R. (2018) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371921.lg05 · Cited by 2
Chapter 4. Psychiatric Assessment and Pharmacological Treatment
Ferretti, C. J., Taylor, B. P., Shinall, J., & Hollander, E. (2018) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371921.lg04 · Cited by 2
Pediatric Psychopharmacology Trials: Beyond Efficacy
Emslie, G. J. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15101269 · Cited by 2
El Masri, S., Kowalczyk, O. S., Chiu, T. H., Criaud, M., Lukito, S., Mazibuko, N., Salazar de Pablo, G., Perez Rodriguez, V., Makos, O., Lam, S.-L., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1676472 · Cited by 1
“There is evidence that guanfacine decreases arousal in animal models (82) and people with addiction (83), and decreases physiological parameters that are related to arousal like blood pressure and pulse in children with ADHD (40, 84).”
Analysis of Electrocardiogram Signal and Ammonia Concentration For Clustering ASD Condition
Marchelliant, M. B., Aripin, A., & Wulandari, S. A. (2021) · International Seminar on Application for Technology of Information and Communication (iSemantic) · doi:10.1109/isemantic52711.2021.9573237 · Cited by 1
Autism spectrum disorder in children and adolescents: Treatment options
Bhatia, R. (2022) · Current Psychiatry · doi:10.12788/cp.0234 · Cited by 1
Rebello, G. N. (2018) · Current clinical psychiatry · doi:10.1007/978-3-319-94458-6_16 · Cited by 1
Autism in Prader-Willi Syndrome
Singh, D., & Mozdzer, E. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108886727.006 · Cited by 1
Trinari, E., Noronha, N., Papola, D., Devji, T., Navarro, T., de Camargo, O. K., & Iorio, A. (2026) · Clinical Medicine Insights Pediatrics · doi:10.1177/11795565261442820 · Cited by 1
Child and Adolescent Psychiatric Disorders
Thom, R. P., Prince, J. B., & Rubin, D. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00039-4 · Cited by 1
Chapter 60. Treatment of Child and Adolescent Disorders
Wagner, K., & Pliszka, S. R. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as60 · Cited by 1
Co-occurring Anxiety in a Child With Autism and ADHD
Daffner, M. S., Savant, D., Blakey-Armstrong, A., Thom, R. P., Howe, Y. J., Fogler, J., & Diekroger, E. A. (2025) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000001388 · Cited by 1
Clonidine in 50 Children with Intellectual Disability: A Naturalistic Study
Swanepoel, A., Maitra, R., Botros, M., Puttaswamaiah, S., & Liew, A. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1177/10445463251366159 · Cited by 1
Alpha-2 Adrenergic Agonists Reduce Heavy Alcohol Drinking and Improve Cognitive Performance in Mice
Quadir, S. G., Lepeak, L., Miracle, S. A., Collu, R., Velte, O., He, Y., Öztürk, Z., Rohl, C. D., Sabino, V., & Cottone, P. (2026) · eNeuro · doi:10.1523/eneuro.0368-25.2026 · Cited by 1
Elbeltagi, Y. M., Rasool, A. O. A. R. E., Elkashlan, A. M., & Al‐Beltagi, M. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v15.i2.117274 · Cited by 1
Mayes, S. D., Andino, M. V., Mattison, R. E., & Waschbusch, D. A. (2026) · Journal of Psychopathology and Behavioral Assessment · doi:10.1007/s10862-026-10317-0 · Cited by 1
Focus on Autism and Related Conditions
Yu, C., & King, B. H. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150030 · Cited by 1
Self-citationAutism Spectrum and Other Developmental Disorders and ADHD
McLaren, J., Lichtenstein, J. D., Bessen, S. Y., & Baldwin, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-64251-2_9 · Cited by 1
Psychopharmacology of Autism Spectrum Disorder
Ozdemir, S., Keary, C. J., Joshi, G., Ceranoglu, A. T., & McDougle, C. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-46295-6_25 · Cited by 1
Self-citationScott, H., Creedon, J., & Sanderson, J. (2022) · Autism and child psychopathology series · doi:10.1007/978-3-031-06120-2_19 · Cited by 1
Biomedical Interventions for Autism Spectrum Disorder
Lim, J. J., & Anagnostou, E. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-20792-1_20 · Cited by 1
Chapter 28. Treating Hyperactivity in Children With Pervasive Developmental Disorders
Scahill, L. D. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379521.lg28 · Cited by 1
Self-citationIdiopathic Autism Spectrum Disorder
Carroll, H. M., Thom, R. P., & McDougle, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-76269-7_1 · Cited by 1
Self-citationZappia, K. J., & Erickson, C. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-78143-8_12 · Cited by 1
Brown, R. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96023-6.00044-0 · Cited by 1
Rothärmel, M. (2019) · theses.fr (ABES) · doi:10.70675/e8883013z1f99z4729z9f22z3ebbd6f1586a · Cited by 2
Zur Therapie von ADHS bei komorbiden Autismus-Spektrum-Störungen
Poustka, L. (2016) · psychopraxis neuropraxis · doi:10.1007/s00739-016-0337-7
Pharmacotherapy of Attention-Deficit, Hyperactivity, and Impulsiveness in Autism Spectrum Disorder
Propper, L., & Halawa, N. (2016) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2016.21.3.10
Advances in Understanding Autism Spectrum Disorder
Gialloreti, L. E., Curatolo, P., & Mazzone, L. (2017) · Journal of Pediatric Neurology · doi:10.1055/s-0037-1602814
"CareMe": a new way to face problem behaviors at school.
Iovino, L., Vita, S., & Mennitto, A. (2019)
Management and treatment of autism spectrum disorders
Simonoff, E. A. (2020) · doi:10.1093/med/9780198713005.003.0030
Williams, Z. J., & McPartland, J. C. (2021) · Springer eBooks · doi:10.1007/978-3-319-91280-6_102086
Williams, Z. J., & McPartland, J. C. (2017) · Springer eBooks · doi:10.1007/978-1-4614-6435-8_102086-1
Bibliography: Psychiatric Treatment of Children and Adolescents
(2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140106
Psychopharmacology in Prader-Willi Syndrome
Singh, D., Mozdzer, E., & Pinkhasov, A. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108886727.013
PHARMACOLOGICAL TREATMENT OF AUTISM SPECTRUM DISORDERS: DIRECTIONS AND PROSPECTS
Боднарь, Л. А. (2020) · International Medical Journal · doi:10.37436/2308-5274-2020-4-9
A Review of Emotional Awareness of Adolescents with Asperger Syndrome
Relka, G. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr231016123129
Chapter 65. Treatment of Individuals With Intellectual Developmental Disorder
Stratigos, K. A., Katz, J., & Hong, D. S. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as65
Chapter 66. Treatment of Autism Spectrum Disorder
Hegarty, J. P., & Hardan, A. Y. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as66
Hartley-McAndrew, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15682-3.00008-0
Neurological evaluation and management of autism spectrum disorder
Goodspeed, K., Haffner, D. N., Golla, S., Morris, M. A., & Evans, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00042-x
Psychopharmacology for Autism and Neurodevelopmental Disorders
Cochran, D., Jalnapurkar, I. R., Palmer, A. C., Venuti, L., & Frazier, J. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_7
Mental Health Disorders in Young Children with Autism Spectrum Disorders
Jang, J., Couch, L. K., Hong, E. S., Goldin, R. L., & Megerian, J. T. (2024) · Autism and child psychopathology series · doi:10.1007/978-3-031-64499-3_28
Myers, S. M., & Challman, T. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824060-1.00038-9
Chapter 2. Psychiatric Assessment and Treatment
Ferretti, C. J., Taylor, B. P., Frankini, C., & Hollander, E. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379521.lg02
Otizm Spektrum Bozuklukları “Klinisyenler İçin Klinik Deneyimler Penceresinden Güncel Veriler”
ÇELİK, Y. S., Macit, Ş. S., Yamak, Y. H., Tunca, R. D., GÜRBÜZ, Ş., Aydos, B. S., Acehan, T., Öz, T., Kaşak, M., Aliyev, E. S. A., et al. (2024) · Bidge Yayınları eBooks · doi:10.70269/mz8qfxw818dl
Psychopharmacology Considerations for Children Aged under 6 Years
Romanowicz, M., Pease, E. R., Tarikogullari, I., PON, N. C., & Gleason, M. M. (2025) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2024.08.003
Keary, C. J., Simon, N., & Tourjee, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-76269-7_5
Prescribing in Children and Adolescents
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg005.pub2
Alpha-2 Agonists in Autism Spectrum Disorder
Henneberry, E. A., & Erickson, C. A. (2025) · Oxford University Press eBooks · doi:10.1093/oso/9780197635841.003.0028
Chapter 3. Neurodevelopmental Disorders
(2017) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371457.lg03
Palumbo, M. L., Keary, C. J., & McDougle, C. J. (2023) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375332.lg07
Self-citationChapter 2. Attention-Deficit/Hyperactivity Disorder
Schumacher, L. T., & Greenhill, L. L. (2023) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375332.lg02
Chintalapally, S., Rajanala, K., & Upadhyay, A. K. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1655348
Chapter 2. Attention-Deficit/Hyperactivity Disorder
Falkowitz, S. B., Akbar, N., & Greenhill, L. L. (2017) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371266.lg02
Arora, A. (2023) · Open Archive (Karolinska Institutet)
Metadata
- Authors
- Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network
- Affiliations
- Seattle Children's Hospital (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2015-12-01
- Volume
- 172
- Issue
- 12
- Pages
- 1197-1206
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1933613998
- Cited by
- 201
- References
- 38
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 24 · 2023: 18 · 2022: 21 · 2021: 22 · 2020: 25 · 2019: 15 · 2018: 14 · 2017: 11 · 2016: 16 · 2015: 2
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Yale University
- National Institutes of Health (UL1TR000454)
- National Institute of Mental Health (R01MH86927, R01MH086927, R01MH83739, R01MH083707, R01MH083739, R01MH083747)
- National Center for Research Resources (UL1RR024139)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Keywords
- guanfacine, autism spectrum disorder, hyperactivity, impulsivity, distractibility, ADHD medication, Aberrant Behavior Checklist, working memory, motor planning, blood pressure, adverse events, children
- MeSH terms
- Autism Spectrum Disorder, Adolescent, Child, Child, Preschool, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Hyperkinesis, Male, Memory, Short-Term, Neuropsychological Tests, Psychomotor Performance, Guanfacine, Treatment Outcome, Adrenergic alpha-2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.